Group 1 - The company announced a leadership change, with Jin Xuekun stepping down as General Manager and Yang Xia appointed as the new General Manager effective September 8, 2025 [3] - Yang Xia is the founder and actual controller of the company, holding 67.77 million shares, which accounts for 58.89% of the company's total equity [3] - The company also reported the resignation of independent director Zhang Jinxin and the transition of Li Fei to a representative director role [3] Group 2 - The company plans to raise up to 2 billion yuan by issuing no more than 7.1757 million shares to strategic investors, representing 6.24% of its pre-issue total equity [4] - Yang Xia signed a share transfer agreement to sell 5.7533 million shares to Hangzhou Jiushi at a price of 243.84 yuan per share, totaling 1.403 billion yuan [4] - Both strategic investors, Yang Xia and Hangzhou Jiushi, are ultimately controlled by Zhong Shanshan, who has invested 3.4 billion yuan into the company [4] Group 3 - The core business of the company focuses on the research, production, and sales of high-end implantable medical devices made from type A recombinant humanized collagen [5] - In the first half of 2025, the company achieved revenue of 859 million yuan, a year-on-year increase of 42.43%, with a gross margin of 90.68% and a net profit attributable to shareholders of 392 million yuan, up 26.65% year-on-year [5]
锦波生物70后女董事长杨霞新任总经理，“钟睒睒系”获新任董事提名